report
STI Watch Newsletter, July 2024
In the second quarter of this year, there have been exciting new reports and updates on guidelines that could help better inform our efforts and ultimately reduce STIs.
Project
Accelerating the development and delivery of STI prevention
AVAC’s work to advance advocacy for STI prevention and integrate it with HIV prevention and global health equity involves supporting a network of advocates, expanding research literacy, and identifying priorities for the field.
Sexually transmitted infections (STIs) are widespread, remain difficult to prevent, and can have severe health consequences, including increased risk for HIV acquisition. While most STIs are curable, they often go undiagnosed and untreated because they tend to cause few or no initial symptoms. Available diagnostics are often too costly to use for routine screening in many low to middle income countries (LMICs), and to date few vaccines exist to address the most common STIs.
Despite the scope and urgency of the problem, STIs receive little public policy or community attention. These infections are often stigmatizing and their effects are most devastating among groups with little political power, such as adolescent girls and young women, sex workers, gay men, and other men who has sex with men.
STIs intersect with HIV and other key priorities for global health equity- developing an advocacy agenda to expedite research, development and rollout of strategies to test for and prevent STIs that is integrated into a broader response is fundamental to global health. Current knowledge and technology suggest breakthroughs are possible and could deliver better, affordable diagnostics and new prevention options.
STIs intersect with the concerns of many vibrant advocacy communities including those working in HIV, sexual and reproductive health, cancer, infertility, and maternal and newborn health. AVAC draws from these communities to raise awareness of STI advocacy, and interest and expertise in scientific research on STI vaccines or diagnostics.
Expanding and advancing the pipeline of research and development for diagnostics and vaccines, along with driving policies and funding to bolster use of the diagnostics that already exist, are essential for prevention across global health.
AVAC and partners provide a host of resources to track and translate research related to STI prevention.
A growing network of STI advocates are accelerating the development of a pipeline of new diagnostics and vaccines. This work depends on champions to make the connection between a robust pipeline of STI prevention products, reduced STI prevalence, reduced HIV risk, and dramatic strides in the improved health of women and other key populations.
With ready access to STI-focused data and information provided by the resources above, advocates are identifying baseline data, gaps and resource needs; and consolidating messages and advocacy priorities. This in turn informs collaborations with health and political leaders to set goals for research, investment, policy, planning, and integrated programs for STI and HIV prevention.
report
In the second quarter of this year, there have been exciting new reports and updates on guidelines that could help better inform our efforts and ultimately reduce STIs.
factsheet
DoxyPEP is a post-exposure prophylaxis used to prevent the acquisition of some bacterial STIs after sex. DoxyPEP is inexpensive, easily tolerated, and widely available. However, questions remain regarding who will benefit most from DoxyPEP and how to implement this strategy broadly to ensure equitable access.
report
This report is one of few to track funding trends in vaccine and diagnostics R&D, and pipeline investments for some of the most common STIs, including chlamydia, genital herpes, gonorrhea, hepatitis B, human papillomavirus (HPV), syphilis, and trichomoniasis.